Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of a novel small molecule combination therapy for the treatment of a broad range of cancer indications. Aminex has advanced AMXT 1501 + DFMO through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients.
Looking for a particular Aminex Therapeutics employee's phone or email?
The Aminex Therapeutics annual revenue was $811000 in 2026.
Mark Burns is the Founder, President and CSO of Aminex Therapeutics.
6 people are employed at Aminex Therapeutics.
Aminex Therapeutics is based in Kirkland, Washington.
The NAICS codes for Aminex Therapeutics are [54, 541711, 54171, 541, 99, 5417].
The SIC codes for Aminex Therapeutics are [80, 283, 28].